Exact Sciences (EXAS) Stock Forecast & Price Target

Q: What is EXAS’s average 12-month price target, according to analysts?

Based on analyst ratings, Exact Sciences Corp.’s 12-month average price target is 63.50.

Q: What is EXAS’s upside potential, based on the analysts’ average price target?

Exact Sciences Corp. has 47.13% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is EXAS a Buy, Sell or Hold?

Exact Sciences Corp. has a consensus rating of Strong Buy which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.

Q: What is Exact Sciences Corp.’s price target?

The average price target for Exact Sciences Corp. is 63.50. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $75.00 ,the lowest forecast is $46.00. The average price target represents 47.13% Increase from the current price of $43.16.

Q: What do analysts say about Exact Sciences Corp.?

Exact Sciences Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

Q: How can I buy shares of EXAS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

3,324 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EXAS Analyst Ratings

Strong Buy

14 Buy

3 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Exact

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EXAS Stock 12 Month Forecast

Average Price Target

$63.50

▲(47.13% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $63.50 with a high forecast of $75.00 and a low forecast of $46.00. The average price target represents a 47.13% change from the last price of $43.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","59":"$59","76":"$76","50.5":"$50.5","67.5":"$67.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,50.5,59,67.5,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.76,49.855384615384615,51.950769230769225,54.04615384615384,56.14153846153846,58.23692307692308,60.332307692307694,62.427692307692304,64.52307692307693,66.61846153846153,68.71384615384615,70.80923076923077,72.90461538461538,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.76,48.97076923076923,50.18153846153846,51.39230769230769,52.60307692307692,53.81384615384615,55.02461538461538,56.23538461538462,57.44615384615385,58.65692307692308,59.86769230769231,61.07846153846154,62.28923076923077,{"y":63.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.76,47.62461538461538,47.489230769230765,47.35384615384615,47.21846153846154,47.08307692307692,46.94769230769231,46.81230769230769,46.676923076923075,46.54153846153846,46.40615384615385,46.27076923076923,46.135384615384616,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$75.00

Average Price Target$63.50

Lowest Price Target$46.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$47

Hold

8.90%

Upside

Reiterated

08/07/25

Exact Sciences' overall stock score is primarily driven by its strong earnings call performance and positive corporate events, which highlight strategic advancements and increased guidance. However, significant profitability challenges and bearish technical indicators weigh down the score. The negative valuation metrics further contribute to a cautious outlook.

Daniel BrennanTD Cowen

TD Cowen

$75→$66

Buy

52.92%

Upside

Reiterated

08/07/25

Exact Sciences: Strategic Moves and Strong Performance Justify Buy Rating Despite Market Overreaction

William BonelloCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

David WestenbergPiper Sandler

Piper Sandler

$70

Buy

62.19%

Upside

Reiterated

08/07/25

Piper Sandler Sticks to Its Buy Rating for Exact Sciences (EXAS)

Patrick B DonnellyCiti

Citi

$75→$65

Buy

50.60%

Upside

Reiterated

08/07/25

Citi Sticks to Their Buy Rating for Exact Sciences (EXAS)

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

08/07/25

Exact Sciences: Strategic Positioning and Growth Potential Bolstered by Freenome Agreement

Vijay KumarEvercore ISI

Evercore ISI

$68→$64

Buy

48.29%

Upside

Reiterated

08/07/25

Evercore ISI Sticks to Their Buy Rating for Exact Sciences (EXAS)

Eve BursteinBernstein

Bernstein

$70→$60

Buy

39.02%

Upside

Reiterated

08/07/25

Bernstein Sticks to Their Buy Rating for Exact Sciences (EXAS)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$67

Buy

55.24%

Upside

Reiterated

08/07/25

Exact Sciences (EXAS) Gets a Buy from Stifel Nicolaus

Puneet SoudaLeerink Partners

Leerink Partners

$90→$70

Buy

62.19%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Its Buy Rating for Exact Sciences (EXAS)

Luke SergottBarclays

Barclays

$65→$55

Buy

27.43%

Upside

Reiterated

08/07/25

Barclays Sticks to Its Buy Rating for Exact Sciences (EXAS)

Conor McNamaraRBC Capital

RBC Capital

$54→$46

Hold

6.58%

Upside

Reiterated

08/07/25

Exact Sciences (EXAS) Receives a Hold from RBC Capital

Unknown AnalystUBS

Not Ranked

UBS

$61→$53

Hold

22.80%

Upside

Reiterated

08/07/25

UBS Remains a Hold on Exact Sciences (EXAS)

Subbu NambiGuggenheim

Guggenheim

$60

Buy

39.02%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Exact Sciences (EXAS)

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

$75

Buy

73.77%

Upside

Reiterated

08/06/25

Exact Sciences: Strong Financial Performance and Strategic Initiatives Justify Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$47

Hold

8.90%

Upside

Reiterated

08/07/25

Daniel BrennanTD Cowen

TD Cowen

$75→$66

Buy

52.92%

Upside

Reiterated

08/07/25

Exact Sciences: Strategic Moves and Strong Performance Justify Buy Rating Despite Market Overreaction

William BonelloCraig-Hallum

Craig-Hallum

―

Buy

―

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

David WestenbergPiper Sandler

Piper Sandler

$70

Buy

62.19%

Upside

Reiterated

08/07/25

Piper Sandler Sticks to Its Buy Rating for Exact Sciences (EXAS)

Patrick B DonnellyCiti

Citi

$75→$65

Buy

50.60%

Upside

Reiterated

08/07/25

Citi Sticks to Their Buy Rating for Exact Sciences (EXAS)

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

08/07/25

Exact Sciences: Strategic Positioning and Growth Potential Bolstered by Freenome Agreement

Vijay KumarEvercore ISI

Evercore ISI

$68→$64

Buy

48.29%

Upside

Reiterated

08/07/25

Evercore ISI Sticks to Their Buy Rating for Exact Sciences (EXAS)

Eve BursteinBernstein

Bernstein

$70→$60

Buy

39.02%

Upside

Reiterated

08/07/25

Bernstein Sticks to Their Buy Rating for Exact Sciences (EXAS)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$67

Buy

55.24%

Upside

Reiterated

08/07/25

Exact Sciences (EXAS) Gets a Buy from Stifel Nicolaus

Puneet SoudaLeerink Partners

Leerink Partners

$90→$70

Buy

62.19%

Upside

Reiterated

08/07/25

Leerink Partners Sticks to Its Buy Rating for Exact Sciences (EXAS)

Luke SergottBarclays

Barclays

$65→$55

Buy

27.43%

Upside

Reiterated

08/07/25

Barclays Sticks to Its Buy Rating for Exact Sciences (EXAS)

Conor McNamaraRBC Capital

RBC Capital

$54→$46

Hold

6.58%

Upside

Reiterated

08/07/25

Exact Sciences (EXAS) Receives a Hold from RBC Capital

Unknown AnalystUBS

Not Ranked

UBS

$61→$53

Hold

22.80%

Upside

Reiterated

08/07/25

UBS Remains a Hold on Exact Sciences (EXAS)

Subbu NambiGuggenheim

Guggenheim

$60

Buy

39.02%

Upside

Reiterated

08/06/25

Guggenheim Reaffirms Their Buy Rating on Exact Sciences (EXAS)

Kyle Mikson CFACanaccord Genuity

Canaccord Genuity

$75

Buy

73.77%

Upside

Reiterated

08/06/25

Exact Sciences: Strong Financial Performance and Strategic Initiatives Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exact Sciences

1 Month

xxx

Success Rate

25/40 ratings generated profit

Average Return

+7.00%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +7.00% per trade.

3 Months

xxx

Success Rate

11/17 ratings generated profit

Average Return

+12.94%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +12.94% per trade.

1 Year

Doug SchenkelWolfe Research

Success Rate

15/21 ratings generated profit

Average Return

+32.50%

reiterated a buy rating 11 months ago

Copying Doug Schenkel's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +32.50% per trade.

2 Years

xxx

Success Rate

25/40 ratings generated profit

Average Return

+115.10%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +115.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXAS Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EXAS has received 29 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. EXAS average Analyst price target in the past 3 months is 63.50.

Each month's total comprises the sum of three months' worth of ratings.

EXAS Financial Forecast

EXAS Earnings Forecast

Next quarter’s earnings estimate for EXAS is <$0.01 with a range of -$0.16 to $0.17. The previous quarter’s EPS was -$0.01. EXAS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year EXAS has Outperformed its overall industry.

EXAS Sales Forecast

Next quarter’s sales forecast for EXAS is $806.25M with a range of $787.00M to $815.44M. The previous quarter’s sales results were $811.09M. EXAS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.08% of the time in the same period. In the last calendar year EXAS has Outperformed its overall industry.

EXAS Stock Forecast FAQ

What is EXAS’s average 12-month price target, according to analysts?

Based on analyst ratings, Exact Sciences Corp.’s 12-month average price target is 63.50.

What is EXAS’s upside potential, based on the analysts’ average price target?

Exact Sciences Corp. has 47.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EXAS a Buy, Sell or Hold?

Exact Sciences Corp. has a consensus rating of Strong Buy which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.

What is Exact Sciences Corp.’s price target?

The average price target for Exact Sciences Corp. is 63.50. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $46.00. The average price target represents 47.13% Increase from the current price of $43.16.

What do analysts say about Exact Sciences Corp.?

Exact Sciences Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of EXAS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Exact Sciences (EXAS) Stock Forecast & Price Target

EXAS Analyst Ratings

EXAS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exact Sciences

EXAS Analyst Recommendation Trends

EXAS Financial Forecast

EXAS Earnings Forecast

EXAS Sales Forecast

EXAS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts